Memphasys Limited
IG7.F
0.00 EUR
1 day: -25.0% (-0.00 EUR)
The alert is saved directly without jumping back to the homepage.
Price alerts for IG7.F
Please log in to view and save price alerts.
Finanzen
Company info
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Aktuelle News
-
Memphasys signs national supply agreement with Monash IVF for Felix sperm selection system
Vorschau anzeigen
Memphasys Ltd (ASX:MEM, OTC:MPHSF, FRA:IG7) has executed a 12-month exclusive national supply agreement with Monash IVF Group Ltd (ASX:MVF) (ASX) for the rollout of its Felix™ automated sperm selection system across Australia. The agreement follows more than 10 years of collaboration between...
-
Memphasys secures first South-East Asian commercialisation agreement for Felix™
Vorschau anzeigen
Memphasys Ltd (ASX:MEM, OTC:MPHSF, FRA:IG7) has secured its first commercial partnership in South-East Asia, signing an exclusive agreement with TMSC Viet Nam Medical Technology Company Limited for the sale and distribution of its Felix™ sperm separation system in Vietnam. The two-year...